{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-025539","form_type":"8-K","ticker":"VXRT","cik":"0000072444","company_name":"Vaxart, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.714597+00:00","generated_at":"2026-05-31T11:25:02.537468+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vaxart Q2 net loss narrows to $16.5M; BARDA award up to $453M for COVID Phase 2b","bullets":["Net loss per share $0.09 vs $0.16 YoY; revenue $6.4M (from $1.4M) on BARDA contract.","Cash and investments $62.6M at June 30; received ~$64.7M BARDA payment post-quarter.","BARDA Project NextGen award up to $453M to support 10,000-subject Phase 2b COVID trial vs mRNA comparator.","Enrollment for Phase 2b expected in H2 2024 pending FDA alignment; cash runway into 2026.","Norovirus vaccine: in discussions with FDA on correlates of protection; evaluating Phase 2b/challenge study."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-025539","json":"https://secwatch.observer/filing/0001437749-24-025539.json","markdown":"https://secwatch.observer/filing/0001437749-24-025539.md","text":"https://secwatch.observer/filing/0001437749-24-025539.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/72444/000143774924025539/0001437749-24-025539-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/72444/000143774924025539/vxrt20240529_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:25:02.537468+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}